Work

Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics

Year: 2019

Type: review

Abstract: More oncology biologics are becoming available for subcutaneous (sc.) administration and are expected to provide useful therapeutic options. We evaluated evidence published in the past 5 years to assess the humanistic and economic impact of sc. versus intravenous administration of approved cancer therapies and identify outcomes favoring either administration route. These publications focused predominantly on healthcare resource utilization and economic outcomes, demonstrating resource and cost savings with sc. administration. Patients reported a better health-related quality of life and preference for sc. formulations. Time-and-motion study analyses confirmed the convenience of sc. administration. These findings suggest that future availability of sc. oncology biologics, especially anti-PD-1/PD-ligand 1 antibodies due to their increased utility in various malignancies, may be beneficial for patients, healthcare providers and payers.

Source: Future Oncology

DOI: 10.2217/fon-2019-0368

Authors: Kenneth C Anderson, Ola Landgren, Rebecca C Arend, Jeffrey Chou, Ira A Jacobs

Institutions: Harvard University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, Pfizer (United States)

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Multiple Myeloma Research Foundation, Leukemia and Lymphoma Society, National Institutes of Health